ORKA

Oruka Therapeutics reported positive Week 16 Phase 2b EVERLAST-B data for ORKA-001 in moderate-to-severe psoriasis, with 61% of patients on the 600 mg dose achieving complete skin clearance and a safety profile broadly comparable to placebo.

Oruka Therapeutics (NASDAQ:ORKA) reported interim week 16 results from EVERLAST-B, a Phase IIb dose-ranging study of ORKA-001 in adults with moderate-to-severe plaque psoriasis.

Key TakeawaysOruka Therapeutics shares rose 12% after ORKA-001, its drug for psoriasis, completely cleared the skin of 61% of patients on the high dose at Week 16 of its Phase 2b EVERLAST-B trial.

Oruka said about 61% of patients receiving the highest 600 mg dose achieved PASI 100 after week 16, compared with none receiving placebo.

Oruka Therapeutics has had a sharp run over the past year, yet the recent pullback puts a spotlight on a different question for investors. Is the current share price still in line with what the company’s book value can reasonably support?

Oruka Therapeutics' (ORKA) lead program of long-acting IL-23 in moderate-to-severe psoriasis maintai

Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.

Oruka Therapeutics recently reported positive Week 28 data from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis, showing deepening clinical responses and a safety profile consistent with the IL-23p19 class.

Oruka Therapeutics Inc.

Oruka Therapeutics, Inc. (NASDAQ:ORKA) shares fell 5% on Wednesday morning after the biotechnology company reported Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis.